Shennong gene issued shares to buy assets once again rejected the Commission hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulated trading client sina finance App: Live on-line blogger to guide your entries you earn take can make you my son, the reporter Wang editor Qiu Jiang Shennong gene acquisition of Hainan Bo Lian rice gene Technology Co Ltd (hereinafter referred to as "Bo Lian gene) the latest program again the Commission was rejected. The difference between before and after the two assets or earnings forecast scheme is the key factor leading to the plan crashed. Shennong gene announcement today, in September 19th the company received notification to the Commission, the Commission listed companies merger and reorganization of the audit committee held in September 19th 2016 sixty-eighth merger working meeting of the audit committee, the company issued shares to buy assets did not get through. This is the second in March 18th this year after the acquisition again rejected the commission. The acquisition program back company initially disclosed, Shennong gene intends to issue 165 million shares to 4.23 yuan per share price, the price of 700 million yuan acquisition by the control tower group and chairman Huang Peijin and Sun Minhua 3 trading partners, holds 61.52% stake in Bo Lian gene, value-added rate of 56.85%. The main problem of the trading program that appeared in the target company’s profitability. Announcements, Bo Lian gene until 2020 turnaround, the 2016 to 2019 is expected to net profit forecast values were -25.84 million, -160.3 million, -3470.73 million, -3277.14 million, -1.05 million yuan, and in 2018 before the non operating income. The Commission in March this year for the audit opinion and the application materials show the target company 2016-2019 forecast continued losses, the transaction is not conducive to improving the quality of assets of listed companies, improve the financial situation and enhance the sustainable profitability, does not comply with the "major asset restructuring of listed companies management approach" the provisions of article forty-third. However, Shennong gene did not give up on the wave lotus gene acquisition. In late April, Shennong gene re evaluation of the transaction after the disclosure of the report. The adjusted performance commitments, Bo Lian gene 2016-2020 annual net profit after deduction of non will be not less than 15 million 326 thousand and 700 yuan, 11 million 816 thousand and 500 yuan, 13 million 543 thousand yuan, 11 million 632 thousand and 200 yuan and 70 million 621 thousand and 100 yuan. The difference between before and after the profit forecast immediately caused Bo Lian gene Shenzhen attention. The Shenzhen Stock Exchange issued the Shennong gene letter of inquiry, the primary concern is the company’s latest earnings forecast reasons to modify the evaluation and rationality. The company responded that regard, the profit forecast is to modify the gene Bo Lian business strategy adjustment as well as the subject of the company’s second new patent assessment and application based on new rice varieties. But the response is clearly not recognized by the commission. Currently, the listed company has not yet received the Commission shall not approve the official documents, the company received the Commission will not approve the official documents will be announced separately. Enter the Sina financial stocks] discussion相关的主题文章: